Catalent Resources

iPSCs, a Universal Starting Material for Therapies

iPSCs are a viable option for use as a starting material for allogeneic cell therapies offering advantages and potential as a universal source.

Quality Considerations for a Growing Gene Therapy Field

Shorter timelines for clinical trials means being ready earlier for the quality requirements of late-stage trials and regulatory reviews.

Commercial Readiness Using 'Manufacturing by Design'

Allogeneic T-cell therapies are moving toward late-stage clinical trials and commercial registration with the promise of having these breakthrough therapies.